Literature DB >> 11149951

A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes.

T Ilani1, D Ben-Shachar, R D Strous, M Mazor, A Sheinkman, M Kotler, S Fuchs.   

Abstract

Dopamine is a major neurotransmitter in the central nervous system, and its receptors are associated with a number of neuropathological disorders such as Parkinson's disease and schizophrenia. Although the precise pathophysiology of schizophrenia remains unknown, the dopaminergic hypothesis of the illness assumes that the illness results from excessive activity at dopamine synapses in the brain. Because, at present, the diagnosis of schizophrenia relies on descriptive behavioral and symptomatic information, a peripheral measurable marker may enable a simpler, more rapid, and more accurate diagnosis and monitoring. In recent years, human peripheral blood lymphocytes have been found to express several dopamine receptors (D(3), D(4), and D(5)) by using molecular biology techniques and binding assays. It has been suggested that these dopamine receptors found on lymphocytes may reflect receptors found in the brain. Here we demonstrate a correlation between the D(3) dopamine receptor on lymphocytes and schizophrenia and show a significant elevation of at least 2-fold in the mRNA level of the D(3), but not of the D(4), dopamine receptor in schizophrenic patients. This increase is not affected by different antipsychotic drug treatments (typical or atypical). Moreover, nonmedicated patients exhibit the same pattern, indicating that this change is not a result of medical treatment. We propose the D(3) receptor mRNA on blood lymphocytes as a marker for identification and followup of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149951      PMCID: PMC14638          DOI: 10.1073/pnas.98.2.625

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Neurotransmitter interactions in schizophrenia-therapeutic implications.

Authors:  A Carlsson; N Waters; M L Carlsson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

Review 2.  Dopamine in schizophrenia.

Authors:  J Hietala; E Syvälahti
Journal:  Ann Med       Date:  1996-12       Impact factor: 4.709

Review 3.  Dopamine receptors and transporters in Parkinson's disease and schizophrenia.

Authors:  P Seeman; H B Niznik
Journal:  FASEB J       Date:  1990-07       Impact factor: 5.191

4.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

5.  Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?

Authors:  B Bondy; M Ackenheil; R Elbers; M Fröhler
Journal:  Psychiatry Res       Date:  1985-05       Impact factor: 3.222

Review 6.  Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.

Authors:  J A Lieberman
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

7.  An analysis of lymphocyte 3H-N-methyl-scopolamine binding in neurological patients. Evidence of altered binding in Alzheimer's disease.

Authors:  P Ferrero; P Rocca; C Eva; P Benna; N Rebaudengo; L Ravizza; E Genazzani; B Bergamasco
Journal:  Brain       Date:  1991-08       Impact factor: 13.501

8.  Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients.

Authors:  P Karlsson; L Smith; L Farde; C Härnryd; G Sedvall; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

9.  Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes.

Authors:  N Takahashi; Y Nagai; S Ueno; Y Saeki; T Yanagihara
Journal:  FEBS Lett       Date:  1992-12-07       Impact factor: 4.124

10.  Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease.

Authors:  Y Nagai; S Ueno; Y Saeki; F Soga; M Hirano; T Yanagihara
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

View more
  45 in total

Review 1.  Impact of molecular medicine on neuropsychiatry: the clinician's perspective.

Authors:  J M Ryan; R Loy; P N Tariot
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Authors:  Henry Silver; Yael Chertkow; Orly Weinreb; Lena Danovich; Moussa Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

3.  mRNA expression of dopamine receptors in peripheral blood lymphocytes of computer game addicts.

Authors:  Nasim Vousooghi; Seyed Zeinolabedin Zarei; Mitra-Sadat Sadat-Shirazi; Fatemeh Eghbali; Mohammad Reza Zarrindast
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

4.  D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells.

Authors:  Biswarup Basu; Chandrani Sarkar; Debanjan Chakroborty; Subhalakshmi Ganguly; Saurav Shome; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 5.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

Review 6.  Dopamine, T cells and multiple sclerosis (MS).

Authors:  Mia Levite; Franca Marino; Marco Cosentino
Journal:  J Neural Transm (Vienna)       Date:  2017-03-10       Impact factor: 3.575

7.  Increased mRNA levels of the mitochondrial complex I 75-kDa subunit. A potential peripheral marker of early onset schizophrenia?

Authors:  Claudia Mehler-Wex; J Catharina Duvigneau; Romana T Hartl; Dorit Ben-Shachar; Andreas Warnke; Manfred Gerlach
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-06-20       Impact factor: 4.785

8.  Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration.

Authors:  Jonathan Kipnis; Michal Cardon; Hila Avidan; Gil M Lewitus; Sharon Mordechay; Asya Rolls; Yael Shani; Michal Schwartz
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

9.  MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway.

Authors:  J Xiao; Y Li; E Prandovszky; S S Karuppagounder; C C Talbot; V L Dawson; T M Dawson; R H Yolken
Journal:  Neuroscience       Date:  2014-03-18       Impact factor: 3.590

10.  Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.

Authors:  Julia Pinsonneault; Wolfgang Sadée
Journal:  AAPS PharmSci       Date:  2003-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.